Cytokinetics (CYTK) Gains from Investment Securities (2016 - 2024)
Historic Gains from Investment Securities for Cytokinetics (CYTK) over the last 13 years, with Q4 2024 value amounting to $1.2 million.
- Cytokinetics' Gains from Investment Securities changed N/A to $1.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $19.6 million, marking a year-over-year increase of 8665.97%. This contributed to the annual value of $19.6 million for FY2024, which is 6664.36% up from last year.
- As of Q4 2024, Cytokinetics' Gains from Investment Securities stood at $1.2 million.
- Over the past 5 years, Cytokinetics' Gains from Investment Securities peaked at $77.9 million during Q1 2021, and registered a low of -$2.8 million during Q4 2021.
- Its 5-year average for Gains from Investment Securities is $12.4 million, with a median of $3.3 million in 2021.
- Data for Cytokinetics' Gains from Investment Securities shows a peak YoY increase of 694222.42% (in 2021) and a maximum YoY decrease of 34482.16% (in 2021) over the last 5 years.
- Over the past 5 years, Cytokinetics' Gains from Investment Securities (Quarter) stood at $1.1 million in 2020, then crashed by 344.82% to -$2.8 million in 2021, then skyrocketed by 146.29% to $1.3 million in 2022, then surged by 707.76% to $10.5 million in 2023, then plummeted by 88.76% to $1.2 million in 2024.
- Its Gains from Investment Securities was $1.2 million in Q4 2024, compared to $18.4 million in Q1 2024 and $10.5 million in Q1 2023.